Effect of pimecrolimus on interleukin-33 level in mice with atopic dermatitis and asthma
10.3760/cma.j.issn.1673-4904.2019.11.009
- VernacularTitle: 吡美莫司对特异性皮炎合并哮喘小鼠气道重塑的影响研究
- Author:
Xueying LI
1
;
Feng WANG
2
;
Zhaoqing HAN
1
;
Jian′ou QIAO
1
Author Information
1. Department of Respiratory Medicine,Shanghai Ninth People′s Hospital, Shanghai Jiaotong University of Medical, Shanghai 200011, China
2. Department of Thoracic Surgery, Shanghai Ninth People′s Hospital, Shanghai Jiaotong University of Medical, Shanghai 200011, China
- Publication Type:Journal Article
- Keywords:
Asthma;
Interleukin;
Atopic dermatitis;
Pimecrolimus
- From:
Chinese Journal of Postgraduates of Medicine
2019;42(11):999-1005
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the potential mechanism of pimecrolimus in airway remodeling of atopic dermatitis (AD) and asthma mice.
Methods:Female BALB/c mice were randomly divided into three groups: control group, atopic dermatitis group and pimecrolimus treatment group. The cell in bronchoalveolar lavage fluid (BALF) was calculated by Ray-Jimsa staining. The structural changes in lung tissue and skin tissue were observed by hematoxylin-eosin (HE) staining, and the level of interleukin (IL)-33, IL-5, IL-13 in serum was detected by enzyme-linked immunosorbent assay (ELISA). The expressions of type 1 collagen (Col1) in the airway of mice were detected by RT-PCR and Western blotting. And western blotting was also used to determine the activation of mitogen-activated protein kinase P38 (P38MAPK) and mitogen-and stress-activated protein kinase 1 (MSK1) in the lungs of mice.
Results:Compared with those in the control group, the total number of leukocytes in bronchoalveolar lavage fluid (BALF) and the expression levels of IL-33, IL-13 and IL-5 in serum of atopic dermatitis group were significantly higher, and the difference was statistically significant (P < 0.05). In the atopic dermatitis group, the phosphorylation of P38MAPK and MSK1 protein was increased (1.50 ± 0.43 vs. 0.80 ± 0.43, 1.39 ± 0.08 vs. 0.62 ± 0.08) and the expression of Col1 protein and protein (1 vs. 3.20 ± 0.59, 1.40 ± 0.12 vs. 0.13 ± 0.16) was increased, and the difference was statistically significant (P < 0.05). After pimecrolimus treatment, the number of leukocytes in BALF, the levels of IL-33, IL-5 and IL-13 in serum (213.13 ± 11.89, 657.97 ± 86.47, 143.82 ± 33.02), the phosphorylation of P38MAPK and MSK1 protein in lung tissue (0.10 ± 0.04, 0.85 ± 0.05), and the expression of Col1 mRNA and Col1 protein were decreased (0.61 ± 0.22, 0.48 ± 0.08), and the difference was statistically significant (P < 0.05). The edema of lung and skin tissue and the infiltration of inflammatory cells were alleviated.
Conclusions:Pimecrolimus can alleviate the inflammation and airway remodeling in mice by inhibiting the activation of IL-33 related pathways, thereby reducing the incidence of asthma.
